No CrossRef data available.
Article contents
Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression
Published online by Cambridge University Press: 16 April 2020
Abstract
Sleep studies in patients with major depression receiving the new selective norepinephrine and serotonin reuptake inhibitor (SNRI) duloxetine are lacking.
Polysomnography in 10 patients with major depression (7 males, 39.9 ± 7.6 years, HAMD-21 score: 23.6 ± 5.6) was recorded twice, before and after 7-14 days of treatment with duloxetine.
A significant (p < 0.01) increase from baseline to endpoint was found for amount of stage 3 sleep (21.0 ± 10.7 to 37.4 ± 20.1 minutes) and REM latency (58.5 ± 31.1 to 193.6 ± 72.6 minutes). Amount of REM sleep significantly (p < 0.01) decreased from 94.8 ± 34.5 to 51.5 ± 42.5 minutes.
These results partly differ from those in healthy subjects receiving duloxetine.
- Type
- Poster Session 2: Depressive Disorders
- Information
- European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S234
- Copyright
- Copyright © European Psychiatric Association 2007
Comments
No Comments have been published for this article.